Standard Biotools Inc (NASDAQ:LAB) — Market Cap & Net Worth
Market Cap & Net Worth: Standard Biotools Inc (LAB)
Standard Biotools Inc (NASDAQ:LAB) has a market capitalization of $271.66 Million ($271.66 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15384 globally and #3630 in its home market, demonstrating a 0.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Standard Biotools Inc's stock price $0.73 by its total outstanding shares 392578808 (392.58 Million). Also see LAB total assets for a full breakdown of the balance sheet.
Standard Biotools Inc Market Cap History: 2015 to 2026
Standard Biotools Inc's market capitalization history from 2015 to 2026. Data shows change from $4.24 Billion to $286.58 Million (-20.20% CAGR). Also see cash flow conversion of Standard Biotools Inc for how efficiently the company converts equity into cash flow.
Index Memberships
Standard Biotools Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #421 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1498 of 3165 |
Weight: Standard Biotools Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Standard Biotools Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Standard Biotools Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Standard Biotools Inc (LAB) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.89x
Standard Biotools Inc's market cap is 5.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.86 Billion | $104.45 Million | -$75.98 Million | 27.36x | N/A |
| 2017 | $2.31 Billion | $101.94 Million | -$60.53 Million | 22.68x | N/A |
| 2018 | $3.38 Billion | $112.96 Million | -$59.01 Million | 29.96x | N/A |
| 2019 | $1.37 Billion | $117.24 Million | -$64.79 Million | 11.65x | N/A |
| 2020 | $2.36 Billion | $138.14 Million | -$53.02 Million | 17.05x | N/A |
| 2021 | $1.54 Billion | $130.58 Million | -$59.24 Million | 11.79x | N/A |
| 2022 | $459.32 Million | $97.95 Million | -$190.10 Million | 4.69x | N/A |
| 2023 | $867.60 Million | $106.34 Million | -$74.66 Million | 8.16x | N/A |
| 2024 | $687.01 Million | $174.43 Million | -$138.88 Million | 3.94x | N/A |
| 2025 | $502.50 Million | $85.33 Million | -$74.90 Million | 5.89x | N/A |
Competitor Companies of LAB by Market Capitalization
Companies near Standard Biotools Inc in the global market cap rankings as of September 18, 2026. Review Standard Biotools Inc (LAB) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Standard Biotools Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #126 globally with a market cap of $177.76 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #235 globally with a market cap of $107.45 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Abbott Laboratories | NYSE:ABT | $177.76 Billion | $102.23 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.77 |
| #235 | Stryker Corporation | NYSE:SYK | $107.45 Billion | $280.13 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Standard Biotools Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Standard Biotools Inc's market cap moved from $4.24 Billion to $ 286.58 Million, with a yearly change of -20.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $286.58 Million | -42.97% |
| 2025 | $502.50 Million | -26.86% |
| 2024 | $687.01 Million | -20.81% |
| 2023 | $867.60 Million | +88.89% |
| 2022 | $459.32 Million | -70.15% |
| 2021 | $1.54 Billion | -34.67% |
| 2020 | $2.36 Billion | +72.41% |
| 2019 | $1.37 Billion | -59.63% |
| 2018 | $3.38 Billion | +46.35% |
| 2017 | $2.31 Billion | -19.09% |
| 2016 | $2.86 Billion | -32.65% |
| 2015 | $4.24 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Standard Biotools Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $271.66 Million USD |
| MoneyControl | $271.66 Million USD |
| MarketWatch | $271.66 Million USD |
| marketcap.company | $271.66 Million USD |
| Reuters | $271.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more